Ryogen is Awarded Patents on Two Human Genes

Share Article

Ryogen LLC is awarded two U.S. Patent Nos. 7,468,266, titled "Isolated genomic polynucleotide fragments that encode human lipoprotein-associated phospholipase A2," and 7,470,522 , titled "Isolated genomic polynucleotide fragments encoding human resistin and the human syntaxin binding protein 2.

Ryogen LLC, a genetic company headquartered in Suffern, New York, announced today that it has been awarded by the U.S. Patent and Trademark Office two patents on human genes.

U.S. Patent Nos. 7,468,266 titled "Isolated genomic polynucleotide fragments that encode human lipoprotein-associated phospholipase A2" and 7,470,522 , titled "Isolated genomic polynucleotide fragments encoding human resistin and the human syntaxin binding protein 2" cover isolated genomic polynucleotide fragments that encode human lipoprotein-associated phospholipase A2, human resistin and human syntaxin binding protein 2, vectors and hosts containing these fragments and fragments hybridizing to noncoding regions as well as antisense oligonucleotides to these fragments and methods of using these fragments to obtain the coded proteins and to diagnose, treat, prevent and/or ameliorate a pathological disorder.

"I am very pleased that the U.S. Patent Office awarded us these patents," said Dr. James W. Ryan, the named inventor and Chief Scientist of Ryogen.

"The claimed genes are directed to proteins, which are thought to play important roles in serious human diseases," Dr. Ryan continued. "Human lipoprotein-associated phospholipase A2 is one of the enzymes that can initiate synthesis of proinflammatory mediators. The enzyme appears to play a central role in the development of atherosclerosis and is regarded as an independent risk factor for coronary artery disease. Its level has been found to be altered in patients with systemic lupus erythematosis, stroke and asthma. Resistin is involved in regulation of insulin effects and is believed to provide a link between obesity and Type 2 diabetes. Human syntaxin binding protein is disposed largely in placenta, lung, liver, kidney, peripheral lymphocytes and pancreas. It plays a role in vesicular transport in non-neuronal tissues."

"The patents are important addition to the Ryogen's patent portfolio," said Valeria Poltorak, Ryogen's Executive Vice President. "We are planning to license the newly issued patents and make these genes widely available for research to promote the development of new methods of genetic diagnostics and treatment," she concluded.

About Ryogen LLC
Ryogen LLC, headquartered in Suffern, NY, is a genomic start-up and a portfolio company of an idea incubator, operated by IP Holdings LLC, also located in Suffern, NY. Ryogen is managed by General Patent Corporation, a premier patent licensing and enforcement boutique.

For further information on Ryogen contact Valeria Poltorak, Ryogen LLC, Montebello Park, 75 Montebello Road, Suffern, NY 10901; telephone: (845) 368-4000 x111.

About IP Holdings LLC
IP Holdings LLC is an IP-centric merchant banking organization which operates an idea incubator with a focus on patent commercialization. IP Holdings LLC is affiliated with General Patent Corporation, a premier patent licensing and enforcement boutique. For further information on IP Holdings contact IP Holdings LLC, Montebello Park, 75 Montebello Road, Suffern, NY 10901; telephone: (845) 368-4000 or visit http://www.ip-holdings.com.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Alec Schibanoff
Visit website